{
    "clinical_study": {
        "@rank": "157926", 
        "acronym": "RTxIMprobio", 
        "arm_group": [
            {
                "arm_group_label": "probiotics", 
                "arm_group_type": "Experimental", 
                "description": "Probiotics supplementation group. Probiotics intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.\nProbiotics is composed of Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium lactis, L. rhamnosus, B. longum and B. bifidum."
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo group. Placebo intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.\nPlacebo is composed of starch.Probiotics and placebo were similar in appearance, taste."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effect of probiotics to improve the intestinal\n      microbiome in malignancy patients who get pelvic/abdominal radiotherapy."
        }, 
        "brief_title": "Effects of Probiotics Supplementation on Intestinal Microbiome in Malignancy Pts(Get Pelvic/Abdominal Rtx)", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Cancer", 
        "detailed_description": {
            "textblock": "Pelvic/abdominal radiotherapy carries a risk of complications. Acute complications include\n      diarrhea, abdominal pain, inflammatory change in the small intestine. Radiation creates\n      changes in bacterial microbiome, the vascular permeability of the mucosal cells and in\n      intestinal motility.  Probiotics were known to improve gastrointestinal function. This is a\n      randomized, double-blind, placebo-controlled study involving 26 patients designed to\n      evaluate the effect of probiotics to change the intestinal microbiome in in patients\n      undergoing concurrent pelvic/abdominal RT."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who current diagnosis of gynecologic cancer or rectal cancer and never\n             previously received radiation therapy and will use for the first time radiotherapy at\n             department of radiation oncology, Seoul National University Hospital.\n\n          -  ECOG performance status (PS) of 0, 1, or 2.\n\n          -  signed written informed consent.\n\n          -  Patients who get pelvic/abdominal radiotherapy.\n\n        Exclusion Criteria:\n\n          -  People who use antibiotics that can affect intestinal microorganism growth within one\n             month before the study.\n\n          -  Patients who use probiotics within one month before the study.\n\n          -  Patients received neoadjuvant chemotherapy.\n\n          -  Acute enteritis symptoms (diarrhea, abdominal pain, nausea, vomiting) for the\n             patient.\n\n          -  Patients diagnosed with inflammatory bowel disease.\n\n          -  Patients suspected gastrointestinal infections and other infectious diseases.\n\n          -  Suspected infections from blood tests : Excessive rise in WBC, ESR, CRP\n\n          -  Suspected renal insufficiency from blood tests"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01706393", 
            "org_study_id": "SNUH-Cell-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "probiotics", 
                "description": "Effects of probiotics supplementation on intestinal microbiome; 2capsule bid orally for six weeks, 1capsule(500mg) Started eating probiotics  one week prior of radiation therapy.", 
                "intervention_name": "probiotics (six probiotic cultures)", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "Placebo intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "probiotics", 
            "intestinal microbiome", 
            "radiotherapy"
        ], 
        "lastchanged_date": "April 18, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-744"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Double Blind Placebo Controled Randomized Trial, Effects of Probiotics Supplementation on Intestinal Microbiome in Malignancy Patients Who Get Pelvic/Abdominal Radiotherapy", 
        "overall_contact": {
            "email": "khjae@snu.ac.kr", 
            "last_name": "Hak Jae Kim, MD", 
            "phone": "+82-2-2072-2520"
        }, 
        "overall_contact_backup": {
            "email": "drdemian@snu.ac.kr", 
            "last_name": "Seung Wan Kang, MD,PhD", 
            "phone": "+82-2-747-7422"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Hak Jae Kim, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Comparison of overall microbial communities in fecal samples between probiotics treated patients and control cancer patients receiving radiation therapy.\nTo determine preventing effect of probiotics against radiation enteropathy, all the bacterial species level taxon derived from fecal samples of cancer patients will be identified by massive sequencing analysis and relative abundance of each taxon between two groups will be statistically compared.\nIn addition, overall microbial composition, kind of species and their abundance, in two groups will be compared with clustering method such as UPGMA and PCoA and the variation values between two groups will be calculated.\nIn the current study, we will determine the effectiveness of probiotics for the prevention of radiation induced complications with these two comparative analysis methods.", 
            "measure": "Changes of gut microbial communities in malignancy patients receiving pelvic/abdominal radiotherapy after probiotics administration to prevent radiation enteropathy.", 
            "safety_issue": "No", 
            "time_frame": "42 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01706393"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Gastrointestinal symptoms will be scored according the Gastrointestinal symptom rating scale before and after RTx.\nDiarrhea will be graded weekly according the Common Toxicity Criteria system.", 
            "measure": "Prevention of any grade of diarrhea and gastrointestinal symptoms", 
            "safety_issue": "No", 
            "time_frame": "42 days"
        }, 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}